Orphanet: Phase 3b, Randomized, Double blind, Placebo controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of TezacaftorIvacaftor TEZIVA in an Orkambi experienced Population Who Are Homozygous for the F508del CFTR Mutation
x

Search for a networks

* (*) mandatory field

Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population Who Are Homozygous for the F508del-CFTR Mutation

  • Type of network : Multinational clinical trials
  • Geographic coverage : Global
  • Funding body(ies) : -
  • Sponsor : VERTEX PHARMACEUTICALS, INC.
  • Website
  • Coordinator of multinational clinical trial

  • INFORMATION NOT PROVIDED
  • Institution: Information not provided - US
  • ADDRESS: NOT PROVIDED - US
  • UNITED STATES
  • More information
  • Phone  : -
  • Fax  : -
Last update: October 2018

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.